Despite extensive research it is still debatable whether uric acid is an independent cardiovascular risk factor or merely a marker of cardiovascular disease risk factors such as hypertension, dyslipidaemia and glucose intolerance. 1, 2 In this context it is essential to learn about the effects of medications on uric acid levels.
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Neutral effect of valsartan on serum uric acid and renal function tests
Despite extensive research it is still debatable whether uric acid is an independent cardiovascular risk factor or merely a marker of cardiovascular disease risk factors such as hypertension, dyslipidaemia and glucose intolerance. 1, 2 In this context it is essential to learn about the effects of medications on uric acid levels.
Losartan, an angiotensin II receptor blocker, is known to have an uricosuric effect and can lower serum uric acid levels. 3 There is sparse data on valsartan, a drug from the same class, in terms of its effect on serum uric acid. Therefore, we planned the present study to search for a relation between valsartan therapy and serum uric acid levels. We also checked for valsartan's effect on renal function tests, electrolytes and creatinine clearance.
Patients selected for the study were drawn from outpatient clinics in Ankara University Heart Center and Mersin University Department of Cardiology. The study patients did not have any co-morbid conditions other than hypertension (coronary artery disease, diabetes mellitus, renal failure, heart failure, gout). Valsartan 80-160 mg/day was used as monotherapy in the study group. Patients who were substituted to valsartan because of side effects or inefficacy of a previous medication and enrolled in the study were given a drug-free interval of 1 week for wash-out reasons and none of the patients who preCorrespondence: Dr Tamer Sayin, Ankara Ü niversitesi Kalp Merkezi Hastanesi, (Ankara University Heart Center Hospital), 06590 Cebeci/Ankara, Turkey Received 24 October 2000; accepted 1 January 2001 viously used antihypertensive drugs were on thiazides. Hypertension was defined as a self-reported history of high blood pressure sufficient to warrant a physician's treatment or a measured blood pressure Ͼ160/95 mm Hg. Blood pressure was measured with the patients in a lining (recumbent) position after a 5-min rest with the use of a standard sphygmomanometer using established methods.
Before initiating valsartan treatment all patients had basal levels of uric acid, blood urea nitrogen (BUN), creatinine, sodium (Na), potassium (K) measured and creatinine clearance calculated. After 4 weeks of treatment, office blood pressure readings were taken and uric acid, BUN, creatinine, Na, K and creatinine clearance were studied again.
Statistical analysis was done using a personal computer and the program Statistical Package for Social Sciences 8.0 (SPSS 8.0). Paired t-test was used for comparing basal and post treatment levels of blood pressure readings, blood chemistry analysis and creatinine clearance levels. P value less than 0.05 was considered significant.
There were 32 patients aged 49.4 ± 11.2 (14 female, 18 male). Patients were treated with 80-160 mg valsartan daily. Office blood pressure readings improved from 165.4 ± 6.5 systolic and 97.8 ± 4.2 diastolic to 155.3 ± 6.7 systolic (P Ͻ 0.0001) and 92.4 ± 4.6 diastolic (P Ͻ 0.0001). Serum uric acid levels did not change with 4 weeks of valsartan treatment (P = 0.289, 95% confidence interval 0.295-0.323). BUN, creatinine, sodium, potassium and creatinine clearance levels also did not differ with 4 weeks of valsartan therapy (Table 1) .
There is little known about serum uric acid levels with valsartan treatment in hypertensive individuals. In a small study, 16 patients treated with valsartan were compared with 14 patients receiving perindopril and both medications were reported to decrease uric acid levels, 4 conflicting our data and a recent placebo-controlled detailed study of valsartan on healthy individuals. 5 To our knowledge (by searching the Medline through the internet) this is the largest study to evaluate the effect of valsartan therapy on serum uric acid levels in hypertensive individuals. Because of conflicting results, and small number of patients, a larger, placebocontrolled study investigating the effect of renal handling of uric acid in hypertensive individuals would be probably indicated.
Valsartan at therapeutic dosages, have neutral effect on serum uric acid, renal function tests and electrolytes. 
